Format

Send to

Choose Destination
See comment in PubMed Commons below

Lamivudine useful against hepatitis B-HIV co-infection.

Abstract

AIDS:

Research is showing lamivudine (3TC) is useful against hepatitis B-HIV co-infection in severely immunodeficient HIV-HBV co-infected persons when given 300 mg twice daily. The open-label study cited involved 29 HIV-HBV co-infected persons, with mean CD4+ counts of about 100. Patients were also positive for HBV antigens for at least one year. After six months of treatment with 3TC, all patients tested were negative for HBV-DNA. It was found that when 3TC was stopped, HBV-DNA went up, and when it was resumed, HBV-DNA went down again. While under therapy, patients showed no detectable DNA replication.

PMID:
11362610
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center